Testosterone Enanthate for Secondary Hypogonadism

What Is Secondary Hypogonadism and Why Does the Diagnosis Change Treatment Choices?

Secondary hypogonadism means the testes are functionally intact but receive insufficient stimulation from the hypothalamic-pituitary axis. Total testosterone falls below 300 ng/dL while LH and FSH are low or inappropriately normal (LH <8 mIU/mL), a pattern that distinguishes it clearly from primary hypogonadism. Because the defect sits upstream of the testes, clinicians have a genuine choice between replacing testosterone directly and stimulating the axis to produce it endogenously.

The Endocrine Society's 2018 clinical practice guideline on male hypogonadism states: "We suggest against starting testosterone therapy in patients who are planning fertility in the near future." [1] That recommendation reflects the well-documented suppression of the hypothalamic-pituitary-gonadal (HPG) axis by exogenous androgens. Testosterone enanthate, like all exogenous testosterone formulations, suppresses LH and FSH through negative feedback within days of the first injection, reducing intratesticular testosterone concentrations by roughly 94% and halting spermatogenesis in most men within 6 to 12 weeks. [2]

Common causes of secondary hypogonadism include hyperprolactinemia, Kallmann syndrome, pituitary adenomas, obesity-related suppression, opioid use, and idiopathic hypogonadotropic hypogonadism (IHH). Treating the underlying cause (for example, dopamine agonists for prolactinoma) may normalize testosterone without any androgen therapy at all, so a thorough workup is non-negotiable before prescribing testosterone enanthate. [3]

For men who are older, have completed their families, or have no reversible cause identified, testosterone enanthate remains a well-supported, cost-effective option that reliably normalizes serum testosterone and improves symptoms. [4]

FDA Approval Status and Regulatory Basis for Use in Secondary Hypogonadism

Testosterone enanthate is FDA-approved. The approved indication is "hypogonadism (primary and hypogonadotropic) in males," which explicitly covers secondary (hypogonadotropic) hypogonadism. [5] The drug has been continuously approved since 1953 under NDA 005289 and is listed in the FDA's Orange Book as a reference-listed drug. Branded Delatestryl and numerous generic formulations share this approved indication.

The FDA label specifies that testosterone enanthate is indicated for conditions "associated with a deficiency or absence of endogenous testosterone," including hypogonadotropic hypogonadism caused by pituitary-hypothalamic injury, tumors, or radiation. [5] Using it for secondary hypogonadism is therefore on-label prescribing, not off-label use.

Regulatory confirmation matters clinically because it directly affects prior-authorization decisions and liability. Physicians can document the specific ICD-10 code E23.0 (hypopituitarism) or E23.6 (other disorders of pituitary gland) alongside E29.1 (testicular hypofunction) to support medical necessity. [6]

Clinical Trial Evidence Supporting Testosterone Enanthate in Secondary Hypogonadism

The strongest trial data come from the Testosterone Trials (T-Trials), a coordinated set of seven double-blind, placebo-controlled trials published in the New England Journal of Medicine in 2016. The sexual-function trial (N=470 of the 790-man cohort) showed that testosterone treatment produced a significantly higher percentage of men with increased sexual desire (56.6% vs. 40.3% placebo, P<0.001). [7] The vitality trial demonstrated improved energy scores on the SF-36 vitality subscale (mean difference +2.41 points, P=0.03). [7]

The T-Trials enrolled men aged 65 or older with total testosterone below 275 ng/dL. The majority had secondary or mixed hypogonadism. Testosterone was delivered as a 1% gel in these trials rather than enanthate specifically, but the outcomes are attributed to normalized serum testosterone levels regardless of delivery method, and the FDA label for testosterone enanthate references equivalent bioavailability data. [5][7]

A 2020 systematic review and meta-analysis in The Journal of Clinical Endocrinology and Metabolism analyzed 35 randomized controlled trials (N=5,464) of testosterone therapy across all formulations. The analysis found statistically significant improvements in sexual function (standardized mean difference 0.63 to 95% CI 0.44, 0.82) and modest but significant reductions in fat mass (weighted mean difference -1.6 kg). [8] Testosterone enanthate was among the most commonly studied formulations in the included trials.

For men with idiopathic hypogonadotropic hypogonadism specifically, a 2017 study in the European Journal of Endocrinology tracked 47 patients on testosterone enanthate 250 mg every 3 weeks for 12 months. Mean total testosterone rose from 68 ng/dL at baseline to 487 ng/dL at 6 months. [9] Quality-of-life scores on the Aging Males' Symptoms (AMS) scale improved by a mean of 14.3 points (P<0.001). [9]

Bone mineral density evidence is also relevant because secondary hypogonadism causes faster bone loss than primary hypogonadism due to concurrent estrogen deficiency (testosterone aromatizes to estradiol). The T-Trials bone trial found that testosterone increased spine BMD by 7.5% vs. 0.6% placebo (P<0.001) and femoral neck BMD by 3.8% vs. 1.0% (P<0.001) over 12 months. [10]

Dosing Protocols for Secondary Hypogonadism

Standard FDA-approved dosing for testosterone enanthate in hypogonadism is 50 to 400 mg administered intramuscularly every 2 to 4 weeks. [5] In clinical practice, that range is wide enough to be almost meaningless without additional context, so the following breakdown reflects current prescribing norms supported by pharmacokinetic data.

Weekly 100 mg IM injections produce the steadiest serum testosterone curves. A pharmacokinetic study published in the Journal of Clinical Pharmacology (N=56) showed that weekly 100 mg doses maintained mean trough testosterone between 350 and 600 ng/dL in 78% of subjects, compared with only 41% of subjects achieving that range on biweekly 200 mg injections due to peak-trough swings. [11] Many men on biweekly schedules report energy crashes and mood dips in the 10 to 14 days before their next injection. Weekly injections largely eliminate this. [11]

Biweekly 200 mg IM remains the most commonly prescribed schedule in the United States because it halves injection frequency. Peak serum testosterone typically reaches 800, 1 to 200 ng/dL at 48 to 72 hours post-injection, then falls to 300 to 450 ng/dL by day 14. [5] Some patients tolerate this fluctuation without symptoms; others do not.

Dose titration targets: The Endocrine Society guideline recommends titrating dose to achieve mid-normal range total testosterone of 400 to 700 ng/dL. [1] Check serum testosterone at 3 to 6 months after initiating therapy. For biweekly dosing, draw the sample midway through the dosing interval (day 7). For weekly dosing, draw the trough (just before the next injection).

Subcutaneous injection of testosterone enanthate (using a 25, 27 gauge, 5/8-inch needle, injecting into the abdomen or thigh subcutaneous tissue) has gained traction as a lower-pain alternative. A 2018 study in The Journal of Urology (N=40) found subcutaneous testosterone cypionate achieved equivalent serum levels to IM with significantly lower injection-site pain scores. [12] The pharmacokinetics of enanthate and cypionate are nearly identical (half-lives of 4.5 vs. 8 days, respectively), and the subcutaneous route is considered applicable to enanthate by most endocrinologists, though formal approval language specifies IM administration. [5]

For men with obesity-driven secondary hypogonadism (a common scenario, given that adipose aromatase converts testosterone to estradiol, suppressing the HPG axis), weight loss of 10% body weight has been shown to raise total testosterone by an average of 128 ng/dL without any testosterone therapy. [13] Starting testosterone enanthate without addressing weight may require higher doses to reach target levels and perpetuates HPG suppression unnecessarily in men who could potentially recover endogenous production.

When Fertility-Sparing Alternatives Should Be Used Instead

Testosterone enanthate suppresses spermatogenesis. This is the single most important clinical consideration that distinguishes secondary hypogonadism management from primary hypogonadism management. Men with secondary hypogonadism have functioning testes that can produce sperm if properly stimulated, and exogenous testosterone removes that stimulation.

Human chorionic gonadotropin (hCG) mimics LH and directly stimulates Leydig cells. A 2013 study in Fertility and Sterility (N=37) showed that hCG 3 to 000 IU three times weekly normalized intratesticular testosterone in all subjects and maintained sperm counts above 10 million/mL in 78% over 6 months of therapy. [14] Serum testosterone levels rose to a mean of 512 ng/dL. hCG is the standard fertility-sparing option for men with secondary hypogonadism who want to conceive.

Enclomiphene citrate, a selective estrogen receptor modulator (SERM), blocks hypothalamic estrogen receptors and raises endogenous LH and FSH. A Phase III trial published in BJU International (N=303) showed enclomiphene 12.5 mg daily raised mean testosterone from 202 ng/dL to 431 ng/dL over 3 months while preserving sperm counts above baseline, unlike testosterone gel, which reduced sperm counts by 94% in the comparator arm. [15]

The American Urological Association (AUA) 2018 guideline on male infertility states that clinicians "should not prescribe testosterone therapy to the hypogonadal male who desires fertility." [16] This applies directly to secondary hypogonadism, where hCG and enclomiphene are genuine substitutes rather than adjuncts.

For men who have completed family planning, testosterone enanthate is an entirely appropriate choice. The decision tree is simple: fertility desired now or within 2 years: use hCG or enclomiphene. Fertility not desired or already achieved: testosterone enanthate is appropriate and effective.

Side Effects That Matter Specifically for Secondary Hypogonadism Patients

Several adverse effects carry heightened relevance in the secondary hypogonadism context because the underlying HPG-axis dysfunction can modify risk.

Erythrocytosis (polycythemia): Testosterone stimulates erythropoietin production. Hematocrit above 54% occurred in 5.8% of testosterone-treated men in the T-Trials compared with 0% in placebo, representing a statistically significant difference (P<0.001). [7] Men with secondary hypogonadism from pituitary disease often have baseline anemia, which paradoxically makes them more responsive to testosterone's erythropoietic effect and at higher risk for overcorrection. Draw a CBC at baseline and at 3 months after initiating therapy. [1]

Cardiovascular risk: The TRAVERSE trial (N=5,246, published NEJM 2023) found no significant increase in major adverse cardiovascular events (MACE) in men with hypogonadism and established cardiovascular disease or high CV risk who received testosterone therapy vs. placebo (hazard ratio 1.07 to 95% CI 0.96, 1.20). [17] Atrial fibrillation was higher in the testosterone arm (3.5% vs. 2.4%, P=0.02). [17] Men with secondary hypogonadism from pituitary tumors or Kallmann syndrome do not carry inherently higher CV risk, but those with obesity-driven HPG suppression often have metabolic syndrome, where the TRAVERSE findings are directly applicable.

Lipid changes: Testosterone enanthate reduces HDL cholesterol by an average of 5 to 10 mg/dL, based on a meta-analysis of 58 trials published in JAMA Internal Medicine. [18] LDL changes are variable. Obtain a fasting lipid panel at baseline and at 6 to 12 months.

Sleep apnea worsening: Testosterone can worsen obstructive sleep apnea (OSA). Men with obesity-related secondary hypogonadism frequently have undiagnosed OSA. Screen with the STOP-BANG questionnaire before initiating therapy. If OSA is suspected, order a sleep study first. [1]

Skin and injection-site reactions: Pain, induration, and oil embolism (rare) can occur with IM injection. Rotating injection sites (left vs. right gluteus, or vastus lateralis) reduces local reactions. Subcutaneous administration reduces pain scores by roughly 40% based on patient-reported outcomes in the 2018 Journal of Urology study. [12]

Hypogonadism rebound after discontinuation: Men with secondary hypogonadism who stop testosterone enanthate after more than 12 months of therapy may have prolonged recovery of endogenous testosterone production, sometimes requiring clomiphene or hCG to restart the axis. One retrospective cohort (N=62) found median time to testosterone recovery above 300 ng/dL after stopping TRT was 4.2 months, though 18% had not recovered at 6 months. [19]

Monitoring Schedule After Starting Testosterone Enanthate

Structured monitoring matters because secondary hypogonadism patients often have concurrent pituitary pathology requiring its own surveillance. The Endocrine Society recommends the following intervals for testosterone therapy monitoring. [1]

At 3 to 6 months: serum total testosterone (trough for weekly dosing, mid-interval for biweekly), CBC with hematocrit, PSA (in men over 40), and a symptom review using a validated scale such as the AMS or IIEF-15.

At 12 months: repeat all of the above plus fasting lipid panel and bone mineral density if baseline DEXA showed osteopenia (T-score between -1.0 and -2.5).

Annually thereafter: serum testosterone, hematocrit, PSA, and blood pressure. If hematocrit exceeds 54%, hold the next injection, evaluate for sleep apnea, and reduce dose or frequency once hematocrit returns below 52%. [1]

For men whose secondary hypogonadism is pituitary in origin, MRI surveillance of any known adenoma continues on its own schedule (typically every 1 to 2 years for microadenomas, every 6 to 12 months for macroadenomas) independent of testosterone therapy. [3]

Comparing Testosterone Enanthate to Other Testosterone Formulations in Secondary Hypogonadism

Testosterone enanthate and testosterone cypionate are the two most widely used injectable esters in the United States. Their pharmacokinetics differ only slightly: enanthate has a half-life of approximately 4.5 days vs. 8 days for cypionate. [5] Both are administered IM or subcutaneously, and both cost under $30 per vial in generic form. The choice between them is largely one of availability and patient preference.

Testosterone undecanoate (Aveed, 750 mg IM every 10 weeks) offers the convenience of infrequent dosing but carries an FDA black-box warning for serious pulmonary oil microembolism (POME) reactions and anaphylaxis, requiring a 30-minute post-injection observation period in a certified healthcare facility. [20] For men with secondary hypogonadism from obesity or pituitary disease who may have limited clinic access, the injection frequency advantage of undecanoate may be outweighed by the monitoring requirement.

Topical gels (testosterone 1.62%, brand AndroGel) and patches normalize serum testosterone but carry a transfer risk to female partners and children. A CDC report documented 156 pediatric testosterone-exposure cases between 2010 and 2012 linked to topical testosterone use in household contacts. [21] Injectables eliminate this risk entirely.

Testosterone pellets (Testopel) are implanted subcutaneously every 3 to 6 months. Pellets cannot be removed if side effects emerge. Hematocrit elevation rates with pellets may be higher than with injectables in some cohort data. [22] That makes pellets a less preferred option in secondary hypogonadism patients where titration flexibility is often needed at initiation.

Cost and Insurance Coverage for Testosterone Enanthate in Secondary Hypogonadism

Generic testosterone enanthate 200 mg/mL (10 mL vial) retails for $20, $35 at most U.S. pharmacies. A weekly 100 mg protocol uses 5 mL per month from a 10 mL vial, making monthly drug cost roughly $10, $18 for the medication alone, excluding syringes and needles (approximately $8, $12/month). [23]

Most commercial insurance plans cover testosterone enanthate for documented secondary hypogonadism with appropriate ICD-10 coding and lab evidence. Medicare Part D covers it under most formularies as a Tier 1 or Tier 2 drug. Prior authorization typically requires two lab values below 300 ng/dL drawn in the morning (before 10 a.m.), evidence of symptoms, and documentation ruling out reversible causes. [6]

Medicaid coverage varies by state. Some states require failure of a 90-day trial of lifestyle modification for obesity-related secondary hypogonadism before approving testosterone therapy, though this requirement is inconsistently enforced. [6]